Allogene Therapeutics (ALLO) Accounts Payables (2018 - 2026)
Allogene Therapeutics (ALLO) posted Accounts Payables of $4.9 million for Q1 2026, up 15.53% sequentially from $4.3 million in Q4 2025, and down 2.47% YoY from $5.1 million in Q1 2025.
Allogene Therapeutics (ALLO) Accounts Payables (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Accounts Payables fell 2.47% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 2.47% YoY) and the FY2025 annual result came in at $4.3 million, down 20.84% from the prior year.
- Accounts Payables climbed to $4.9 million in Q1 2026 per ALLO's latest filing, from $4.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $14.7 million in Q1 2023 and troughed at $3.7 million in Q3 2025.
- A 5-year average of $7.8 million and a median of $5.9 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables jumped 68.67% in 2023, then plunged 62.5% in 2025.
- Over 5 years, Accounts Payables stood at $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then declined by 8.53% to $5.4 million in 2024, then dropped by 20.84% to $4.3 million in 2025, then grew by 15.53% to $4.9 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.9 million, $4.3 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 5.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.96 Mn |
| Mar 31, 2026 | 4.93 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 5.51 Mn |
| Jun 30, 2024 | 12.94 Mn |
| Mar 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 5.90 Mn |
| Sep 30, 2023 | 6.21 Mn |
| Jun 30, 2023 | 10.23 Mn |
| Mar 31, 2023 | 14.69 Mn |
| Dec 31, 2022 | 13.89 Mn |
| Sep 30, 2022 | 11.05 Mn |
| Jun 30, 2022 | 9.71 Mn |
| Mar 31, 2022 | 8.71 Mn |
| Dec 31, 2021 | 10.26 Mn |
| Sep 30, 2021 | 11.50 Mn |